Genetically predicted triglyceride lowering through the perturbation of LPL pathway activation targets ANGPTL4, APOC3, and LPL was associated with lower risk of CAD and T2D, and lower apoB. The gene discussed is LPL; the disease is type 2 diabetes mellitus.